The evaluation of genotoxic potential of ornidazole, nitroimidazole, in lymphocyte culture of patients with amebiasis

References

• Bendensky A, Menendez A, Ostrosky-Wegman P (2002). Is metranidazole carcinogenic?. Mutat. Res. 511, 133–144.
   PubMedGoogle Scholar
• Brismar BC, Edlund C, Malmborg AS, Nord CE (1990). Ecological impact of antimicrobial prophylaxis on intestinal microflora in patients undergoing colorectal surgery. Scand J Infect Dis Suppl. 70, 25–30.
   PubMedGoogle Scholar
• Cantelli-Forti G, Aicardi G, Guerra MC, Barbaro AM, Biagi GL (1983). Mutagenicity of a series of 25 nitroimidazoles and two nitro thiazoles in Salmonella typhimurium. Teratog. Carcinog. Mutagen. 3, 51–63.
   PubMedGoogle Scholar
• Cerna M, Dobias L, Hajek V, Rossner P, Sram RJ (1990). Mutagenic activity analysis of body fluids in the first phase of clinical drug trials. Cesk. Farm. 39, 127–130.
   PubMedGoogle Scholar
• Chin JB, Sheinin DM, Rauth AM (1978). Screening for the mutagenicity of nitro-group containing hypoxic cell radiosensitizers using Salmonella typhimurium strains TA 100 and TA98. Mutat. Res. 58, 1–10.
   PubMed Web of Science ®Google Scholar
• Connor TH, Stoeckel M, Evrard J, Legator MS (1977). The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice. Cancer Res. 37, 629–633.
   PubMed Web of Science ®Google Scholar
• Countryman P, Heddle J (1976). The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. Mutat. Res; 41, 321–332.
   PubMed Web of Science ®Google Scholar
• De Meo M, Vanelle P, Bernadini E, Laget M, Maldonado J, Jentzer O, Crozet MP, Dumenil G (1992). Evaluation of the mutagenic and genotoxic activities of 48 nitroimidazoles and related imidazole derivatives by the Ames test and the SOS chromotest. Environ. Mol. Mutagen. 19, 167–181.
   PubMed Web of Science ®Google Scholar
• Edwards DI (1986). Reduction of nitroimidazoles in vitro and DNA damage. Biochem. Pharmacol. 35, 53–58.
   PubMed Web of Science ®Google Scholar
• Elizondo G, Gonsebatt ME, Salazar AM, Lares I, Santiago P, Herrera J, Hong E, Ostrosky-Wegman P (1996). Genotoxic effects of metronidazole. Mutat. Res. 370, 75–80.
   PubMed Web of Science ®Google Scholar
• Gebhart E (1981). Sister chromatid exchanges and structural chromosome aberration in mutagenicity testing. Hum. Genet. 58, 235–254.
   PubMed Web of Science ®Google Scholar
• Gupta RL, Vats V, Juneja TR (1996). Activation of tinidazole, an antiprotozoal drug to a mutagen by mammalian liver S9. Mutat. Res. 370, 195–201.
   PubMed Web of Science ®Google Scholar
• IARC (International Agency for Research on Cancer). (1987). IARC monographs on the evaluation of carcinogenic risk to humans. Suppl. 7. Overall evaluations of Carcinogenicity: An updating of IARC monographs volumes 1–42 (pp 250–252). International Agency for Research on Cance (pp250-252), Lyon.
   Google Scholar
• LaRusso NF, Tomasz M, Müller M, Lipman R (1977). Absence of strand breaks in deoxyribonucleic acid treated with metronidazole. Antimicrob. Agents and Chemo. 13, 19–24.
   Web of Science ®Google Scholar
• Latt S.A (1981). Sister chromatid exchange formation. Annu. Rev. Genet. 15, 11–55.
   PubMed Web of Science ®Google Scholar
• Leal-Garza CH, Montes de Oca-Luna R, Baca-Sevilla S, Garza-Chapa R (1984). Tinidazole and emetine cytogenetic effects evaluated by the micronucleus test in mice. Arch. Invest. Med. 15, 311–316.
   PubMedGoogle Scholar
• Lopez Nigro MM, Gadano AB, Carballo MA (2001). Evaluation of genetic damage induced by a nitroimidazole derivative in human lymphocytes: Tinidazole (TNZ). Toxicol. In Vitro, 15, 209–213.
   PubMed Web of Science ®Google Scholar
• Lopez Nigro MM, Palermo AM, Mudry MD, Carballo MA (2003). Cytogenetic evaluation of two nitroimidazole derivatives. Toxicology In Vitro, 17, 35–40.
   PubMed Web of Science ®Google Scholar
• Ludlum DB, Colinas RJ, Kirk MC, Mehta JR (1988). Reaction of reduced metronidazole with guanosine to form an unstable adduct. Carcinogen. 8, 593–596.
   Google Scholar
• Martelli A, Allavena A, Robbiano L, Mattioli F, Brambilla G (1990). Comparison of the sensitivity of human and rat hepatocytes to the genotoxic effects of metronidazole. Pharmacol. Toxicol. 66, 329–334.
   PubMedGoogle Scholar
• Menendez D, Rojas E, Herrera LA, Lopez MC, Sordo M, Elizondo G, Ostrosky-Wegman P (2001). DNA breakage due to metronidazole treatment. Mutat. Res. 478, 153–158.
   PubMed Web of Science ®Google Scholar
• Oderda G, Ponzetto A, Boero M, Bellis D, Forni M, Vaira D, Ansaldi N (1997). Family treatment of symptomatic children with Helicobacter pylori infection. Ital J Gastroenterol. Hepatol. 29, 509–514.
   PubMedGoogle Scholar
• Perry P and Wolff S (1974). New Giemsa method for the differential staining of sister chromatids. Nature 251, 156–158.
   PubMed Web of Science ®Google Scholar
• Reitz M, Rumpf M, Knitza R (1991). DNA single strand-breaks in lymphocytes after metronidazole therapy. Arzneimittelforschung; 41, 155–156.
   PubMed Web of Science ®Google Scholar
• Robinson DM, Abdel-Rahman SM, Nahata MC (1997). Guidelines for the treatment of Helicobacter pylori in the pediatric population. Ann. Pharmacother. 31, 1247–1249.
   PubMed Web of Science ®Google Scholar
• Rodriguez Ferreiro G, Cancino Badías L, Lopez-Nigro M, Palermo A, Mudry M, González Elio P, Carballo MA (2002). DNA single strand breaks in peripheral blood lymphocytes induced by three nitroimidazole derivatives. Toxicol Lett. 132, 109–115.
   PubMed Web of Science ®Google Scholar
• Roe FJ (1985). Safety of nitroimidazoles. Scand J Infect. Dis. Suppl. 46, 72–81.
   Google Scholar
• Rosenblatt JE, Edson RS (1987). Symposium on antimicrobial agents. Metronidazole. Mayo Clin. Proc. 62, 1013–1017.
   PubMedGoogle Scholar
• Shaheen S, Rani TSH, Begum S, Ishaq M (1993). Effect of tinidazole on in vitro lymphokine production. Medical. Science. Res. 21, 19.
   Google Scholar
• Tocher JH, Edwards DI (1994). Evidence for the direct interaction of reduced metronidazole derivatives with DNA bases. Biochem. Pharmacol. 48, 1089–1094.
   PubMed Web of Science ®Google Scholar
• Tucker JD, Preston RJ (1996). Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Mutat. Res. 365, 147–159.
   PubMed Web of Science ®Google Scholar
• Voogd CE, Van der Stel JJ, Jacobs JJ (1974). The mutagenic action of nitroimidazoles. I. Metronidazole, nimorazole, dimetridazole and ronidazole. Mutat. Res. 26, 483–490.
   PubMed Web of Science ®Google Scholar
• Voogd CE, Van der Stel JJ, Jacobs JJ (1977). The mutagenic action of nitroimidazoles. II. Tinidazole, ipronidazole, panidazole and ornidazole. Mutat. Res. 48, 155–161.
   PubMed Web of Science ®Google Scholar
• Zahoor A, Lafleur MV, Knight RC, Loman H, Edwards DI (1987). DNA damage induced by reduced nitroimidazole drugs. Biochem Pharmacol; 36, 3299–3304.
   PubMed Web of Science ®Google Scholar